A Study Comparing The Efficacy, Safety And Tolerability Of Latanoprost 75, 100 And 125 ug/ml To Xalatan In The Treatment Of Primary Open-Angle Glaucoma And Ocular Hypertension

Back to Search
Print
Bookmark Trial

NCT01379144

Last updated date
Back to Search
Print
Bookmark Trial
FOR MORE INFORMATION
Study Location
Eye Associates Pty Limited
Sydney, New South Wales, 2000, Australia
See other locations
Contact
1-800-718-1021
[email protected]
Related Links

FOR MORE INFORMATION

Contact a representative by phone, email, or visiting the study website. Please see the references below:

By phone

Pfizer Clinical Trials Contact Center

1-800-718-1021

By email

Contact

[email protected]

Call Now

Eligibility Criteria
condition
The disease, disorder, syndrome, illness, or injury that is being studied.
Primary Open Angle Glaucoma, Ocular Hypertension
Sex
Females and Males
Age
Pediatric Trials: 0-17 Years
Adult Trials: 18+ Years
18 + years
Inclusion Criteria
The factors, or reasons, that allow a person to participate in a clinical study.
Show details

- Male or female, 18 years of age or older.

- Primary open angle glaucoma (POAG) or ocular hypertension (OHT) requiring unilateral or bilateral administration of intraocular pressure (IOP) lowering treatment, including patients who were naïve to IOP lowering treatment.

- IOP between ≥ 24 mmHg and ≤ 36 mmHg in at least one eye at the 8 AM time point at baseline/randomization.

Exclusion Criteria
The factors, or reasons, that prevent a person from participating in a clinical study.
Show details


- Closed/barely open anterior chamber angle or a history of acute angle closure.


- A history of discontinued prostaglandin IOP lowering treatment, unless the reason for
discontinuation was participation in a clinical study.


- Ocular surgery or argon laser trabeculoplasty in one or both eyes within 3 months
prior to the screening visit.


- Use or anticipated requirement during the study of any topical medication that was
known to affect IOP.


- Anticipated need to modify systemic medication known to affect IOP (eg,
beta-adrenergic antagonists, alpha-adrenergic agonists, calcium channel blockers,
angiotension converting enzyme inhibitors, and angiotension II receptor antagonists)
during the study period.

NEED INFO?

Questions about a trial? Call or email to reach a Pfizer Clinical Trial Contact Center Representative

Pfizer Clinical Trials Contact Center

1-800-718-1021

[email protected]

Call Now

TRY A NEW SEARCH

Search for Clinical Trials by condition, keyword or trial number. Share your location or enter your city or zip code to find studies near you.

Advanced Search

Based on your search, you may also be interested in

Primary Open Angle Glaucoma, Ocular HypertensionA Study Comparing The Efficacy, Safety And Tolerability Of Latanoprost 75, 100 And 125 ug/ml To Xalatan In The Treatment Of Primary Open-Angle Glaucoma And Ocular Hypertension
NCT01379144
  1. Sydney, New South Wales
  2. Sydney, New South Wales
  3. Adelaide, South Australia
  4. Brno,
  5. Prague 5,
  6. Prague 9,
  7. Praha 2,
  8. Praha 2,
  9. Marseille,
  10. Marseille,
  11. Paris,
  12. Strasbourg,
  13. Thessaloniki,
  14. Lahore, Punjab
  15. Lahore, Punjab
  16. Karachi, Sindh
  17. Karachi, Sindh
  18. Coimbra,
  19. Lisboa,
  20. Matosinhos,
  21. Bangkok,
  22. Bangkok,
  23. Birmingham,
  24. Glasgow,
  25. Sunderland,
ALL GENDERS
18 Years+
years
MULTIPLE SITES
Primary Open Angle Glaucoma, Ocular HypertensionSafety and Efficacy of PF-04217329 in Patients With Glaucoma or Elevated Eye Pressure.
NCT00572455
  1. Artesia, California
  2. Newport Beach, California
  3. Petaluma, California
  4. Poway, California
  5. Daytona Beach, Florida
  6. Fort Myers, Florida
  7. Ormond Beach, Florida
  8. Atlanta, Georgia
  9. Atlanta, Georgia
  10. Morrow, Georgia
  11. Evansville, Indiana
  12. Louisville, Kentucky
  13. Rochester, New York
  14. Charlotte, North Carolina
  15. High Point, North Carolina
  16. Tulsa, Oklahoma
  17. Bristol, Pennsylvania
  18. Philadelphia, Pennsylvania
  19. Charleston, South Carolina
  20. Memphis, Tennessee
  21. Austin, Texas
  22. Austin, Texas
ALL GENDERS
18 Years+
years
MULTIPLE SITES
Advanced Information
Descriptive Information
Brief Title  ICMJE A Study Comparing The Efficacy, Safety And Tolerability Of Latanoprost 75, 100 And 125 ug/ml To Xalatan In The Treatment Of Primary Open-Angle Glaucoma And Ocular Hypertension
Official Title  ICMJE A 4 Week, Dose-Ranging, Multi-Center, Randomized, Double-Masked, Parallel Study Comparing The Efficacy, Safety, And Tolerability Of Latanoprost 75, 100 And 125 ug/ml To Xalatan In The Treatment Of Primary Open-Angle Glaucoma Aand Ocular Hypertension
Brief Summary The primary objective of this study was to compare the change in intraocular pressure (IOP) of three different doses of latanoprost (75, 100 and 125 ug/ml) to that of the marketed 50 ug/ml dose, in a dose ranging study.
Detailed Description Not Provided
Study Type  ICMJE Interventional
Study Phase  ICMJE Phase 2
Study Design  ICMJE Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double (Participant, Investigator)
Primary Purpose: Treatment
Condition  ICMJE
  • Primary Open Angle Glaucoma
  • Ocular Hypertension
Intervention  ICMJE
  • Drug: latanoprost 75 ug

    Eligible patients were randomized to receive 1 of 4 different doses of latanoprost (50, 75, 100 or 125 ug/mL).

    Study medication was supplied in clear bottles. Patients were instructed to instill one drop of study medication in one or both eyes (as instructed by their investigator) once daily in the evening between 7 PM and 9 PM during the entire treatment period. The first dose of study medication was instilled in the evening of the baseline visit and the last dose was instilled in the evening before the Week 4 (Day 28) visit.

  • Drug: latanoprost 100 ug

    Eligible patients were randomized to receive 1 of 4 different doses of latanoprost (50, 75, 100 or 125 ug/mL).

    Study medication was supplied in clear bottles. Patients were instructed to instill one drop of study medication in one or both eyes (as instructed by their investigator) once daily in the evening between 7 PM and 9 PM during the entire treatment period. The first dose of study medication was instilled in the evening of the baseline visit and the last dose was instilled in the evening before the Week 4 (Day 28) visit.

  • Drug: latanoprost 125 ug

    Eligible patients were randomized to receive 1 of 4 different doses of latanoprost (50, 75, 100 or 125 ug/mL).

    Study medication was supplied in clear bottles. Patients were instructed to instill one drop of study medication in one or both eyes (as instructed by their investigator) once daily in the evening between 7 PM and 9 PM during the entire treatment period. The first dose of study medication was instilled in the evening of the baseline visit and the last dose was instilled in the evening before the Week 4 (Day 28) visit.

  • Drug: latanoprost 50 ug

    Eligible patients were randomized to receive 1 of 4 different doses of latanoprost (50, 75, 100 or 125 ug/mL).

    Study medication was supplied in clear bottles. Patients were instructed to instill one drop of study medication in one or both eyes (as instructed by their investigator) once daily in the evening between 7 PM and 9 PM during the entire treatment period. The first dose of study medication was instilled in the evening of the baseline visit and the last dose was instilled in the evening before the Week 4 (Day 28) visit.

Study Arms  ICMJE
  • Experimental: latanoprost 75 ug
    Intervention: Drug: latanoprost 75 ug
  • Experimental: latanoprost 100 ug
    Intervention: Drug: latanoprost 100 ug
  • Experimental: latanoprost 125 ug
    Intervention: Drug: latanoprost 125 ug
  • Active Comparator: latanoprost 50 ug
    Intervention: Drug: latanoprost 50 ug
Publications * Eveleth D, Starita C, Tressler C. A 4-week, dose-ranging study comparing the efficacy, safety and tolerability of latanoprost 75, 100 and 125 ?g/mL to latanoprost 50 ?g/mL (xalatan) in the treatment of primary open-angle glaucoma and ocular hypertension. BMC Ophthalmol. 2012 May 18;12:9. doi: 10.1186/1471-2415-12-9.

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Recruitment Information
Recruitment Status  ICMJE Completed
Actual Enrollment  ICMJE
 (submitted: June 21, 2011)		282
Original Actual Enrollment  ICMJE Same as current
Actual Study Completion Date  ICMJE April 2003
Actual Primary Completion Date March 2003   (Final data collection date for primary outcome measure)
Eligibility Criteria  ICMJE

Inclusion Criteria:

  • Male or female, 18 years of age or older.
  • Primary open angle glaucoma (POAG) or ocular hypertension (OHT) requiring unilateral or bilateral administration of intraocular pressure (IOP) lowering treatment, including patients who were naïve to IOP lowering treatment.
  • IOP between ? 24 mmHg and ? 36 mmHg in at least one eye at the 8 AM time point at baseline/randomization.

Exclusion Criteria:

  • Closed/barely open anterior chamber angle or a history of acute angle closure.
  • A history of discontinued prostaglandin IOP lowering treatment, unless the reason for discontinuation was participation in a clinical study.
  • Ocular surgery or argon laser trabeculoplasty in one or both eyes within 3 months prior to the screening visit.
  • Use or anticipated requirement during the study of any topical medication that was known to affect IOP.
  • Anticipated need to modify systemic medication known to affect IOP (eg, beta-adrenergic antagonists, alpha-adrenergic agonists, calcium channel blockers, angiotension converting enzyme inhibitors, and angiotension II receptor antagonists) during the study period.
Sex/Gender  ICMJE
Sexes Eligible for Study:All
Ages  ICMJE 18 Years and older   (Adult, Older Adult)
Accepts Healthy Volunteers  ICMJE No
Contacts  ICMJE Contact information is only displayed when the study is recruiting subjects
Listed Location Countries  ICMJE Australia,   Czechia,   France,   Greece,   Pakistan,   Portugal,   Thailand,   United Kingdom
Removed Location Countries Czech Republic
 
Administrative Information
NCT Number  ICMJE NCT01379144
Other Study ID Numbers  ICMJE XALA-0091-166
A6111066
Has Data Monitoring Committee No
U.S. FDA-regulated Product Not Provided
IPD Sharing Statement  ICMJE Not Provided
Responsible Party Director, Clinical Trial Disclosure Group, Pfizer, Inc.
Study Sponsor  ICMJE Pfizer
Collaborators  ICMJE Not Provided
Investigators  ICMJE
Study Director:Pfizer CT.gov Call CenterPfizer
PRS Account Pfizer
Verification Date September 2018

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP